Salivary levels of last generation specific pro-resolving lipid mediators (SPMs) (protectin and maresin) in patients with cardiovascular and periodontal disease: A case-control study.
cardiovascular disease
gingivitis
maresin
periodontal disease
periodontitis
protectin
Journal
Journal of periodontal research
ISSN: 1600-0765
Titre abrégé: J Periodontal Res
Pays: United States
ID NLM: 0055107
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
15
01
2021
received:
21
08
2020
accepted:
27
01
2021
pubmed:
3
3
2021
medline:
19
5
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
Periodontal disease and cardiovascular disease (CVD), which are both deemed to be triggered by inflammation, are recognized as public health problems. Evidence of host modulation via pro-resolving lipid shown in previous studies supports a two-way relationship between periodontitis and CVD. Last generation endogenous specific pro-resolution lipid mediators (SPMs) such as protectins (PDs) and maresins (MaRs) may have potential effects on inflammatory pathogenesis via activation and resolution mechanisms. Currently, there are no data on SPM levels in patients with CVD and periodontal disease. We aimed to evaluate salivary levels of PD and MaR in patients with CVD and periodontal disease. At total of 181 individuals comprising of 79 healthy controls (C) and 102 patients with diagnosed CVD were included cross-sectionally. Unstimulated total salivary samples were obtained, and clinical periodontal parameters were determined. Salivary levels of PD and MaR were evaluated by ELISA. The periodontal status of the study population was classified as gingivitis (g) or periodontitis (p). Patients with CVD showed lower sociodemographic characteristics, increased clinical periodontal parameters (p < .05), decreased salivary PD (p < .001), and increased salivary MaR levels (p > .05). In the CVDg group, leukocyte, hemoglobin, hematocrit, and high-density lipoprotein values were higher (p < .05). The CVDp group had a higher neutrophil-to-lymphocyte ratio (p < .05). While the PD level was highest in the Cg group, MaR was highest in the CVDp group. The salivary levels of PD and MaR were independent of other confounders in CVD and periodontal disease (p > .05). PDs and MaRs may play effective roles in pathogenesis associated with worsening cardiometabolic and periodontal status. These SPMs could also be predictors for conversion from a healthy (systemically and periodontally) to diseased state (CVD and/or periodontitis). Elucidation of the role of SPMs in the relationship between periodontal disease and CVD will enable the development of new host modulation strategies in the prevention and treatment of both diseases, and may also constitute an important public health step by increasing the quality of life of patients with CVD and periodontal disease.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Periodontal disease and cardiovascular disease (CVD), which are both deemed to be triggered by inflammation, are recognized as public health problems. Evidence of host modulation via pro-resolving lipid shown in previous studies supports a two-way relationship between periodontitis and CVD. Last generation endogenous specific pro-resolution lipid mediators (SPMs) such as protectins (PDs) and maresins (MaRs) may have potential effects on inflammatory pathogenesis via activation and resolution mechanisms. Currently, there are no data on SPM levels in patients with CVD and periodontal disease. We aimed to evaluate salivary levels of PD and MaR in patients with CVD and periodontal disease.
MATERIALS AND METHODS
METHODS
At total of 181 individuals comprising of 79 healthy controls (C) and 102 patients with diagnosed CVD were included cross-sectionally. Unstimulated total salivary samples were obtained, and clinical periodontal parameters were determined. Salivary levels of PD and MaR were evaluated by ELISA. The periodontal status of the study population was classified as gingivitis (g) or periodontitis (p).
RESULTS
RESULTS
Patients with CVD showed lower sociodemographic characteristics, increased clinical periodontal parameters (p < .05), decreased salivary PD (p < .001), and increased salivary MaR levels (p > .05). In the CVDg group, leukocyte, hemoglobin, hematocrit, and high-density lipoprotein values were higher (p < .05). The CVDp group had a higher neutrophil-to-lymphocyte ratio (p < .05). While the PD level was highest in the Cg group, MaR was highest in the CVDp group. The salivary levels of PD and MaR were independent of other confounders in CVD and periodontal disease (p > .05).
CONCLUSION(S)
CONCLUSIONS
PDs and MaRs may play effective roles in pathogenesis associated with worsening cardiometabolic and periodontal status. These SPMs could also be predictors for conversion from a healthy (systemically and periodontally) to diseased state (CVD and/or periodontitis). Elucidation of the role of SPMs in the relationship between periodontal disease and CVD will enable the development of new host modulation strategies in the prevention and treatment of both diseases, and may also constitute an important public health step by increasing the quality of life of patients with CVD and periodontal disease.
Substances chimiques
CD59 Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
606-615Subventions
Organisme : Unit of Scientific Research Projects, Süleyman Demirel University
ID : TDH-2018-6783
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Collins DR, Tompson AC, Onakpoya IJ, Roberts N, Ward AM, Heneghan CJ. Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews. BMJ Open. 2017;7:e013650.
Eke PI, Dye B, Wei L, Thornton-Evans G, Genco R. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012;91:914-920.
Tonetti MS, Van Dyke TE. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol. 2013;84:S24-S29.
Bale BF, Doneen AL, Vigerust DJ. High-risk periodontal pathogens contribute to the pathogenesis of atherosclerosis. Postgrad Med J. 2017;93:215-220.
Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res. 2005;46:389-403.
Yang Z, Kang L, Wang Y, et al. Role of IL-37 in cardiovascular disease inflammation. Can J Cardiol. 2019;35:923-930.
Wang T, Palucci D, Law K, Yanagawa B, Yam J, Butany J. Atherosclerosis: pathogenesis and pathology. Diagn Histopathol. 2012;18:461-467.
Heiss G, Sharrett AR, Barnes R, Chambless L, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol. 1991;134:250-256.
Gaetti-Jardim E Jr, Marcelino SL, Feitosa AC, Romito GA, Avila-Campos MJ. Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. J Med Microbiol. 2009;58:1568-1575.
Progulske-Fox A, Kozarov E, Dorn B, Dunn W Jr, Burks J, Wu Y. Porphyromonas gingivalis virulence factors and invasion of cells of the cardiovascular system. J Periodont Res. 1999;34:393-399.
Ford PJ, Gemmell E, Hamlet SM, et al. Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosis. Oral Microbiol Immunol. 2005;20(5):296-302.
Rodrigues PH, Reyes L, Chadda AS, et al. Porphyromonas gingivalis strain specific interactions with human coronary artery endothelial cells: a comparative study. PLoS One. 2012;7:e52606.
Hasturk H, Abdallah R, Kantarci A, et al. Resolvin E1 attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol. 2015;35:1123-1133.
Grin PM, Dwivedi DJ, Chathely KM, et al. Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor. Sci Rep. 2018;8(1):10496.
Feng X, Zhang Y, Xu R, et al. Lipopolysaccharide up-regulates the expression of Fcalpha/mu receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. Atherosclerosis. 2010;208(2):396-405.
Van Dyke TE. Proresolving lipid mediators: potential for prevention and treatment of periodontitis. J Clin Periodontol. 2011;38(Suppl 11):119-125.
Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047-2067.
Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N. Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta. 2015;1851:397-413.
Jain A, Aggarwal K, Zhang P. Omega-3 fatty acids and cardiovascular disease. Eur Rev Med Pharmacol Sci. 2015;19(3):441-445.
Serhan CN, Jain A, Marleau S, et al. Reduced inflammation and tissue damage in transgenic rabbits over expressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol. 2003;171:6856-6865.
Hasturk H, Kantarci OT, Arita M, et al. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J. 2006;20:401-403.
Hasturk H, Kantarci A, Goguet-Surmenian E, et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol. 2007;179(10):7021-7029.
Hamilton JA, Hasturk H, Kantarci A, Serhan CN, Van Dyke T. Atherosclerosis, periodontal disease, and treatment with resolvins. Curr Atheroscler Rep. 2017;19(12):57.
Hasturk H, Kantarci A. Activation and resolution of periodontal inflammation and its systemic impact. Periodontol 2000. 2015;69:255-273.
Silness J, Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1964;22:121-135.
Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand. 1963;21:533-551.
Chapple ILC, Mealey BL, Van Dyke TE, et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018;45(Suppl 20):S68-S77.
Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis. Framework and proposal of a new classification and case definition. J Clin Periodontol. 2018;45(Suppl 20):S149-S161.
Millar WJ, Wigle DT. Socioeconomic disparities in risk factors for cardiovascular disease. CMAJ. 1986;134:127-132.
Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Am J Public Health. 1992;82:816-820.
Lauritano D, Lo Muzio L, Gaudio RM, et al. Why should patients with systemic disease and tobacco smokers go to the dentist? J Biol Regul Homeost Agents. 2016;30(2 Suppl 1):135-141.
Buhlin K, Mäntylä P, Paju S, et al. Periodontitis is associated with angiographically verified coronary artery disease. J Clin Periodontol. 2011;38:1007-1014.
Fentoğlu Ö, Köroğlu BK, Hiçyılmaz H, et al. Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia. J Clin Periodontol. 2011;38:8-16.
Fentoğlu Ö, Öz G, Taşdelen P, Uskun E, Aykac Y, Bozkurt FY. Periodontal status in subjects with hyperlipidemia. J Periodontol. 2009;80:267-273.
Chen L, Wei B, Li J, et al. Association of periodontal parameters with metabolic level and systemic inflammatory markers in patients with type 2 diabetes. J Periodontol. 2010;81:364-371.
Fentoğlu Ö, Kırzıoğlu FY, Bulut MT, et al. Serum Lp-PLA2: as a novel viewpoint in periodontal treatment of hyperlipidaemics. Turk J Med Sci. 2015;45:619-626.
Zhou X, Zhang W, Liu X, Zhang W, Li Y. Interrelationship between diabetes and periodontitis: role of hyperlipidemia. Arch Oral Biol. 2015;60(4):667-674.
Fentoğlu Ö, Sözen T, Öz S, et al. Short-term effects of periodontal therapy as an adjunct to anti-lipemic treatment. Oral Dis. 2010;16:648-654.
Birnbaum Y, Ye Y, Lin Y, et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation. 2006;114:929-935.
Furman MI, Gore JM, Anderson FA, et al. Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2004;147:42-48.
Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short-and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010;106:470-476.
Doğan B, Fentoğlu Ö, Kırzıoğlu FY, et al. Lipoxin A4 and neutrophil/lymphocyte ratio: a possible indicator in achieved systemic risk factors for periodontitis. Med Sci Monit. 2015;21:2485-2493.
Hutter J, VeldenUvd VA, Huffels R, Hoek F, Loos B. Lower numbers of erythrocytes and lower levels of hemoglobin in periodontitis patients compared to control subjects. J Clin Periodontol. 2001;28:930-936.
Agarwal N, Kumar VS, Gujjari SA. Effect of periodontal therapy on hemoglobin and erythrocyte levels in chronic generalized periodontitis patients: an interventional study. J Indian Soc Periodontol. 2009;13:6-11.
Yamamoto T, Tsuneishi M, Furuta M, Ekuni D, Morita M, Hirata Y. Relationship between decrease of erythrocyte count and progression of periodontal disease in a rural Japanese population. J Periodontol. 2011;82:106-113.
Canpolat U, Çetin EH, Cetin S, et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost. 2016;22:476-482.
Nagao M, Nakajima H, Toh R, Hirata KI, Ishida T. Cardioprotective effects of high-density lipoprotein beyond its anti-atherogenic action. J Atheroscler Thromb. 2018;25:985-993.
Monteiro AM, Jardini MA, Alves S, et al. Cardiovascular disease parameters in periodontitis. J Periodontol. 2009;80:378-388.
Mahley RW, Mahley LL, Bersot TP, Pepin GM, Palaoglu K. The Turkish lipid problem: low levels of high density lipoproteins. Turkish J Endocrinol Metab. 2002;1:1-12.
Bersot TP, Palaoğlu K, Mahley RW. Managing dyslipidemia in Turkey: suggested guidelines for a population characterized by low levels of high density lipoprotein cholesterol. Anadolu Kardiol Derg. 2002;2:315-322.
Mirza S, Hossain M, Mathews C, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012;57:136-142.
Hegde R, Awan KH. Effects of periodontal disease on systemic health. Dis Mon. 2019;65:185-192.
O'Mahoney LL, Matu J, Price OJ, et al. Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol. 2018;17:98.
Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem. 2010;21:781-792.
Torumtay G, Kırzıoğlu FY, Öztürk Tonguç M, et al. Effects of periodontal treatment on inflammation and oxidative stress markers in patients with metabolic syndrome. J Periodontal Res. 2016;51:489-498.
Di Lenardo D, Silva FRPD, de Carvalho França LF, Carvalho JDS, Alves EHP, Vasconcelos DFP. Evaluation of biochemical parameters present in the saliva of patients with chronic periodontitis: results from a meta-analysis. Genet Test Mol Biomarkers. 2019;23:255-263.
Tobón-Arroyave SI, Isaza-Guzmán DM, Gómez-Ortega J, Flórez-Alzate AA. Salivary levels of specialized pro-resolving lipid mediators as indicators of periodontal health/disease status. J Clin Periodontol. 2019;46(10):978-990.
Elabdeen HRZ, Mustafa M, Szklenar M, Rühl R, Ali R, Bolstad AI. Ratio of pro-resolving and pro-inflammatory lipid mediator precursors as potential markers for aggressive periodontitis. PLoS One. 2013;8:e70838.
Wang CW, Colas RA, Dalli J, et al. Maresin 1 biosynthesis and proresolving anti-infective functions with human-localized aggressive periodontitis leukocytes. Infect Immun. 2015;84(3):658-665.
Lütfioğlu M, Aydoğdu A, Sakallıoğlu E, Alaçam H, Pamuk F. Gingival crevicular fluid interleukin-8 and lipoxin A4 levels of smokers and nonsmokers with different periodontal status: a cross-sectional study. J Periodontal Res. 2016;51:471-480.
Tarannum F, Faizuddin M. Effect of Alox-15 polymorphism on GCF levels of lipoxin-A4 in chronic periodontitis: a preliminary study. Braz Dent J. 2017;28:140-147.
Panjamurthy K, Manoharan S, Ramachandran CR. Lipid peroxidation and antioxidant status in patients with periodontitis. Cell Mol Biol Lett. 2005;10(2):255-264.
Marchesan JT, Girnary MS, Moss K, et al. Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics. Periodontol 2000. 2020;82(1):93-114.
Akalin FA, Işiksal E, Baltacioğlu E, Renda N, Karabulut E. Superoxide dismutase activity in gingiva in type-2 diabetes mellitus patients with chronic periodontitis. Arch Oral Biol. 2008;53:44-52.